Who are Storm Therapeutics's investors?

Storm Therapeutics's investors include Cambridge Innovation Capital, Fast Track Initiative, M Ventures, Pfizer Venture Investments, Seroba Life Sciences, Taiho Ventures, LLC, UTokyo Innovation Platform Co. Ltd., IP Group and 2 more.

How much funding has Storm Therapeutics raised?

Storm Therapeutics has disclosed $56M raised across 1 of its 2 known rounds.

Storm Therapeutics

10 known investors

Find your way into Storm Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Storm Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology. Its therapies address cancer, inflammation, viral infections, and CNS diseases.

Biotech Healthtech Medical Devices

Investors · 10

Cambridge Innovation Capitallisted by Cambridge Innovation CapitalCambridge · $127K – $12.7M

How we know: Cambridge Innovation Capital's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Fast Track Initiativelisted by Fast Track InitiativeTokyo

How we know: fiercebiotech.com · Not right? Tell us

M Ventureslisted by M VenturesAmsterdam · $10.8M

How we know: a partner's Signal profile · fiercebiotech.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · the VCSheet dataset · Not right? Tell us

Seroba Life Scienceslisted by Seroba Life SciencesDublin · $540K – $7.6M

How we know: Seroba Life Sciences's portfolio page · a partner's Signal profile · funding news · Not right? Tell us

Taiho Ventures, LLClisted by Taiho Ventures, LLCMenlo Park

How we know: fiercebiotech.com · Not right? Tell us

UTokyo Innovation Platform Co. Ltd.listed by UTokyo Innovation Platform Co. Ltd.Tokyo

How we know: UTokyo Innovation Platform Co. Ltd.'s portfolio page · fiercebiotech.com · Not right? Tell us

IP GroupreportedLondon

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Pfizer Venturesreported

How we know: fiercebiotech.com · Not right? Tell us

University of Cambridge EnterprisereportedCambridge

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Funding

SEC filings, press & company announcements

$56M disclosed across 1 of 2 rounds · 2019–2026

$56Mseries CApr 2026 · 2 sources
Fast Track Initiative, IP Group, M Ventures, Pfizer Ventures, Taiho Ventures, UTokyo Innovation Platform
Source ↗
Undisclosed amountSeries AMay 2019
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 4

Alnylam PharmaceuticalsAlnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

OrnaOrna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.

Shape TherapeuticsShapeTX develops programmable RNA medicines by combining artificial intelligence with RNA technology to address genetic causes of disease.

Transcode TherapeuticsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.

Companies working in the same space as Storm Therapeutics.

In the news

Storm Therapeutics | EU-Startupseu-startups.com · Jan 2022

Frequently asked questions

What does Storm Therapeutics do?: STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology. Its therapies address cancer, inflammation, viral infections, and CNS diseases.
Who are Storm Therapeutics's investors?: Storm Therapeutics's investors include Cambridge Innovation Capital, Fast Track Initiative, M Ventures, Pfizer Venture Investments, Seroba Life Sciences, Taiho Ventures, LLC, UTokyo Innovation Platform Co. Ltd., IP Group and 2 more.
How much funding has Storm Therapeutics raised?: Storm Therapeutics has disclosed $56M raised across 1 of its 2 known rounds.